Last reviewed · How we verify
IMM-124E
At a glance
| Generic name | IMM-124E |
|---|---|
| Sponsor | Immuron Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model (PHASE2)
- Anti-LPS Antibody Treatment for Pediatric NAFLD (PHASE2)
- A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis (PHASE2)
- Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMM-124E CI brief — competitive landscape report
- IMM-124E updates RSS · CI watch RSS
- Immuron Ltd. portfolio CI